FDA Finalizes Guidance on Food Effect Studies for Oral Drug IND and NDA Programs

Sponsors running oral drug programs under IND or NDA pathways now have binding best-practice expectations from FDA's Office of Clinical Pharmacology on when and how to conduct food effect assessments, with direct implications for prescribing information and pivotal trial sequencing. The final guidance, Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations, codifies a tiered study framework that clinical pharmacology and regulatory affairs teams should map against their current development timelines.

The core requirement is a pilot food effect assessment embedded within the first-in-human single-dose trial. This cohort-level evaluation, subjects dosed in fed and fasted states, is explicitly not a definitive study; its purpose is to inform dosing strategies across subsequent development phases until a to-be-marketed formulation is locked. That distinction carries scheduling weight: teams that defer any food assessment until late-phase risk compressing the window before pivotal safety and efficacy trials begin.

Once the to-be-marketed formulation is identified, FDA expects a pivotal food effect trial to be completed before pivotal safety and efficacy studies commence. The sequencing is deliberate, food-related dosing instructions must be established in time to be accurately reflected in prescribing information. For regulatory affairs leads, this means food effect data should appear in the NDA submission with sufficient characterisation to support labelling, not as a post-approval commitment.

On meal selection, the guidance specifies a high-fat meal as the standard condition for all orally administered drugs, on the basis that high-fat meals produce the largest physiological perturbation to gastrointestinal absorption. Where a significant increase or decrease in absorption is observed under high-fat conditions, evaluation of additional meal types becomes relevant, since lower-fat meals may show attenuated effects that could support less restrictive food intake instructions in labelling. The three-question framework FDA applies, does food affect absorption, which food types drive the effect, and what practical instructions follow, provides a structured audit trail for clinical pharmacology packages.

The guidance was discussed publicly by Dr. Vikram Arya, Associate Director for Therapeutic Review in the Division of Infectious Disease Pharmacology, and Dr. Brian Booth, Director of the Division of Cancer Pharmacology I, both within CDER's Office of Clinical Pharmacology, on the agency's Guidance Recap Podcast released 7 July 2026.

Programs with first-in-human trials already underway should assess whether their existing single-dose protocols accommodate a pilot food effect cohort before the next IND amendment cycle closes.

Source: FDA CDER via What's New: Drugs RSS Feed, 7 July 2026.